HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have been assigned a consensus recommendation of ...

Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...

In the last three months, 11 analysts have published ratings on Sangamo Therapeutics (NASDAQ:SGMO), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...

Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...

Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...

Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm ...

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...

Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") . Such investors are advised to contact Danielle Peyton at ...